Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® Technology. Click here to start the conversation now.
Learn More
At the Serum Institute of India, Vaccine Development Requires Multiplex Assays
Bonus: Pro tips for xMAP® assay developers
Since 1967, the Serum Institute of India has launched more than 20 vaccines, with five more vaccines in the pipeline specifically designed to target infectious diseases that are prevalent in developing countries. Impressively, the institute has produced more than 1.3 billion high-quality, low-cost vaccine doses.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
September 11
Luminex Corporation Declares Third Quarter Cash Dividend
September 6
Luminex Corporation to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
August 6
Luminex Corporation Reports Second Quarter 2018 Financial Results
July 13
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018
June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
IDWeek
October 3-7
San Francisco, California
AMP Annual Meeting
November 1-3
San Antonio, Texas
xMAP® Connect Amsterdam
November 6-7
Amsterdam, Netherlands
